Hematologia Geral
Diretriz para o tratamento da anemia por deficiência de ferro em adultos.
12 Set, 2021 | 22:10hEstudo randomizado | Plasma convalescente não melhora os desfechos e pode ser prejudicial a pacientes hospitalizados com COVID-19.
12 Set, 2021 | 21:56hComunicado de imprensa: Major study finds convalescent plasma doesn’t help seriously ill COVID-19 patients – McMaster University
Conteúdos relacionados:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Comentário no Twitter
A randomized trial in patients hospitalized with COVID-19 showed no benefit and potentially increased harm associated with the use of convalescent plasma, according to a @NatureMedicine paper. https://t.co/7JFhEXLmbA pic.twitter.com/Q3e50Q0I7T
— Nature Portfolio (@NaturePortfolio) September 9, 2021
Interações medicamentosas com anticoagulantes orais diretos: recomendações práticas para clínicos.
12 Set, 2021 | 21:32hSuplemento | Temas atuais sobre tromboembolismo venoso.
8 Set, 2021 | 15:09hPágina principal: Current Issues in Venous Thromboembolism – Postgraduate Medicine
Editorial: Current issues in venous thromboembolism
A review of upper extremity deep vein thrombosis
Outpatient treatment of emergency department patients diagnosed with venous thromboembolism
Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery
Prophylaxis and treatment of COVID-19 related venous thromboembolism
Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients
Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients
Radiologic mimics of pulmonary embolism
A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment
Estudo randomizado | Em pacientes com trombocitopenia imune, a adição de micofenolato mofetil ao regime padrão de glicocorticoide reduziu a doença refratária ou reincidente, mas esteve associada com diminuição na qualidade de vida relacionada à função física e à fadiga.
3 Set, 2021 | 12:42hRevisão sistemática | Em pacientes com hemofilia A ou B, estudos randomizados mostram evidências de que a profilaxia com concentrados de fatores de coagulação, comparada com o tratamento sob demanda, pode reduzir a frequência de sangramentos.
3 Set, 2021 | 11:06hEstudo randomizado | Administração de cetamina em pacientes em crise dolorosa aguda de doença falciforme foi efetiva no controle da dor e reduziu a dose cumulativa de morfina no departamento de emergência.
3 Set, 2021 | 10:58hKetamine Administration for Acute Painful Sickle Cell Crisis: A Randomized Controlled Trial – Academic Emergency Medicine (link para o resumo – $ para o texto completo)
Estudo mostra que pacientes com COVID-19 têm risco mais alto de desenvolver coágulos após cirurgia.
2 Set, 2021 | 11:46hCOVID-19 patients at higher risk of blood clots after surgery, study shows – CIDRAP
Estudo original: SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study – Anaesthesia
Conteúdos relacionados:
ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.
Position statement: Perioperative management of post-COVID-19 surgical patients.
Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery
Estudo mostra que há risco aumentado de sangramento gastrintestinal após tratamento concomitante com glicocorticoides orais em pacientes em uso de anticoagulantes orais não antagonistas da vitamina K.
20 Ago, 2021 | 12:07hGastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants – Heart (link para o resumo – $ para o texto completo)
Comentário no Twitter
In this @Heart_BMJ #Afib sdy @AndersHolt6 et al. found a X2 ⬆️ risk of GI bleeding w/ NOAC💊+oral glucocorticoids⚪ vs NOAC alone 💊
Authors recommend ☝️ close monitoring 👀 or other risk 🛑 mitigation when co-prescribing
📝 https://t.co/CgtgmvnD29#CardioTwitter #cardiology pic.twitter.com/95eCOWxozK
— Copenhagen Cardiovascular Research Center (@CopCard) August 15, 2021
Estudo do NIH mostra que não há nenhum benefício significativo do plasma convalescente para pacientes ambulatoriais de COVID-19 com sintomas iniciais.
19 Ago, 2021 | 12:29hEstudo original: Early Convalescent Plasma for High-Risk Outpatients with Covid-19 – New England Journal of Medicine
Comentário no Twitter
Convalescent plasma did not prevent disease progression in patients seen in EDs within 7 days after the onset #COVID19 symptoms. https://t.co/9gmIK3ntKH #IDTwitter pic.twitter.com/sirzn1uGL0
— NEJM (@NEJM) August 18, 2021